ES2172217T3 - Suspensiones de furoato de mometasona para nebulizacion. - Google Patents

Suspensiones de furoato de mometasona para nebulizacion.

Info

Publication number
ES2172217T3
ES2172217T3 ES98950781T ES98950781T ES2172217T3 ES 2172217 T3 ES2172217 T3 ES 2172217T3 ES 98950781 T ES98950781 T ES 98950781T ES 98950781 T ES98950781 T ES 98950781T ES 2172217 T3 ES2172217 T3 ES 2172217T3
Authority
ES
Spain
Prior art keywords
mometasone furoate
nebulization
suspensions
buffer
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98950781T
Other languages
English (en)
Inventor
David Harris
Joel A Sequeira
Imtiaz A Chaudry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2172217T3 publication Critical patent/ES2172217T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)

Abstract

Una suspensión para nebulizador que comprende agua, monohidrato de furoato de mometasona, un tensioactivo no iónico, cloruro sódico o cloruro potásico y, opcionalmente, un amortiguador del pH.
ES98950781T 1997-10-09 1998-10-06 Suspensiones de furoato de mometasona para nebulizacion. Expired - Lifetime ES2172217T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94811897A 1997-10-09 1997-10-09

Publications (1)

Publication Number Publication Date
ES2172217T3 true ES2172217T3 (es) 2002-09-16

Family

ID=25487304

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98950781T Expired - Lifetime ES2172217T3 (es) 1997-10-09 1998-10-06 Suspensiones de furoato de mometasona para nebulizacion.

Country Status (8)

Country Link
EP (1) EP1033991B1 (es)
JP (1) JP3676674B2 (es)
AT (1) ATE216244T1 (es)
AU (1) AU9674398A (es)
CA (1) CA2305256C (es)
DE (1) DE69804998T2 (es)
ES (1) ES2172217T3 (es)
WO (1) WO1999018971A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
EP1441709A1 (en) * 2001-10-26 2004-08-04 Dey L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
JP2010184937A (ja) * 2001-10-26 2010-08-26 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、キット、吸入溶液を中に有する１容器を作成する方法、および、吸入溶液を作成する方法
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
CA2540005A1 (en) * 2003-09-26 2005-04-07 Schering Corporation Pulmonary disease treatment
ITMI20032054A1 (it) 2003-10-22 2005-04-23 Monteres S R L Processo per la preparazione di sospensioni farmaceutiche da inalare.
ES2388287T3 (es) 2005-01-20 2012-10-11 Eratech S.R.L. Procedimiento para la preparación de suspensiones concentradas de fármacos y kit correspondiente
EP1968548A2 (en) * 2005-12-02 2008-09-17 Elan Pharma International Limited Mometasone compositions and methods of making and using the same
EP2394653A1 (en) 2010-05-26 2011-12-14 Almirall, S.A. Topical pharmaceutical compositions comprising mometasone furoate
CN110051627A (zh) * 2014-09-15 2019-07-26 维罗纳制药公司 包含rpl554的液体吸入制剂
WO2020070599A1 (en) * 2018-10-05 2020-04-09 Glenmark Specialty S.A. Nebulization composition of mometasone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU663471B2 (en) * 1990-09-10 1995-10-12 Merck Sharp & Dohme Corp. Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
HUT67445A (en) * 1991-06-10 1995-04-28 Schering Corp Aerosol formulations containing 1,1,1,2-tetrafluorethane
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias

Also Published As

Publication number Publication date
WO1999018971A1 (en) 1999-04-22
DE69804998T2 (de) 2002-12-12
JP2001519397A (ja) 2001-10-23
CA2305256C (en) 2005-05-17
DE69804998D1 (de) 2002-05-23
ATE216244T1 (de) 2002-05-15
CA2305256A1 (en) 1999-04-22
EP1033991B1 (en) 2002-04-17
AU9674398A (en) 1999-05-03
EP1033991A1 (en) 2000-09-13
JP3676674B2 (ja) 2005-07-27

Similar Documents

Publication Publication Date Title
ES2172217T3 (es) Suspensiones de furoato de mometasona para nebulizacion.
ES2172303T3 (es) Agentes terapeuticos obtenidos por catalisis enzimatica.
ES2180213T3 (es) Tratamiento de lentes de contacto con la ayuda de una solucion acuosa que comprende un carbonato alcalino.
CO4750807A1 (es) Solucion de interferon
CO5700797A2 (es) Composicion de farmaco conjugado
HRP20020198B1 (hr) Formulacija moksifloksacina i kuhinjske soli
MX9300690A (es) Composiciones de champu y agente de suspension del mismo.
ES2193515T3 (es) Composicion farmaceutica que comprende un compuesto triciclico con mejor estabilidad, absortividad y escaso potencial irritativo.
FR2902974B1 (fr) Inhibiteur d'endo-beta-1,4-xylanase et xylanases nouvelles, et produits alimentaires les contenant
DE69636953D1 (de) Lyophilisierte hgf-zubereitungen
ES2191618T3 (es) Suspension de ziprasidona.
AR035266A1 (es) Solucion desinfectante basada en hipoclorito sodico y procedimiento para su preparacion
AR036294A1 (es) Modificador de la forma fisica de agentes agricolas basado en almidon dispersable en agua
BR9903257A (pt) Concentrado de suspensão aquosa contendo tiadiazurona e etefona
CA2189424A1 (en) Non-steroidal anti-inflammatory ophthalmic suspensions
AR039146A1 (es) Composiciones limpiadoras liquidas y empleo de las mismas
BR9900559A (pt) Composição de vidro de tipo sìlico-sodo-cálcico.
AR023815A1 (es) Solucion oral de prucalopride
EA199900962A1 (ru) Композиция солюбилизированного сертралина
NO942341L (no) Flytende, vandig rengjöringsmiddel
DK0497724T3 (da) Middel til desintegration af galdesten
CY1108053T1 (el) Ενωση της κυαμεμαζινης και ενος ατυπου νευροληπτικου
AR020695A1 (es) Metodos para controlar macroinvertebrados en sistemas acuosos
MX9702506A (es) Suspensiones orales de sabeluzol.
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1033991

Country of ref document: ES